Jeil Pharma Holdings KRX:002620KOSPI
제일파마홀딩스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Jeil Pharma Holdings reported revenue of ₩165bn, up 3.1% year on year, and an operating loss of ₩9.9bn. Jeil Pharma Holdings (제일파마홀딩스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Jeil Pharma Holdings quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩165bn | +3.1% | −₩9.9bn | −₩6.2bn |
| Q1 2026 | ₩150bn | -17.4% | ₩3.6bn | ₩4.5bn |
| Q4 2025 derived | ₩154bn | -24.3% | ₩6.6bn | ₩12.9bn |
| Q3 2025 | ₩161bn | -15.1% | ₩18.1bn | ₩14.2bn |
| Q2 2025 | ₩160bn | -18.9% | ₩6.9bn | ₩2.9bn |
| Q1 2025 | ₩182bn | -3.6% | ₩7.1bn | ₩4.6bn |
| Q4 2024 derived | ₩204bn | +0.5% | ₩3.9bn | −₩32.3bn |
| Q3 2024 | ₩190bn | -2.4% | −₩3.3bn | −₩5.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Jeil Pharma Holdings top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Jeil Pharma Holdings news Korean headlines
No articles yet.